Listed by the USPTO as JOHANSEN, PETER N.
Tech Center 1600 • Art Units: 1641 1642 1644 1658 1671
This examiner grants 60% of resolved cases
JOHANSEN, PETER N. is assigned to USPTO Tech Center 1600 and Art Unit 1641. The profile records 228 resolved cases, with a 59.6% allowance rate and a median of 1221 days to allowance. Interview lift is 24.4%, indicating a measurable association between interviews and outcomes in the recorded cases.
The listed companies are Hoffmann-La Roche Inc., Amazon Technologies Inc., and The Board of Trustees of the Leland Stanford Junior University. The associated firms are Leason Ellis LLP, FOLEY HOAG, LLP (General), and MARSHALL, GERSTEIN & BORUN LLP. Practitioners should plan written responses and interviews as complementary tools.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19667436 | COMPOSITIONS AND METHODS FOR TREATING MULTIPLE SCLEROSIS | Non-Final OA | Hoffmann-La Roche Inc. |
| 18271540 | Personalized Longitudinal Analysis of Circulating Material to Monitor and Adapt Neoantigen Cancer Vaccines | Final Rejection | AMAZON TECHNOLOGIES, INC. |
| 18553523 | CLASSIFICATION OF NEUROLOGICAL OR PSYCHIATRIC DISEASE MANIFESTATIONS USING MULTI-DIMENSIONAL CEREBROSPINAL FLUID ANALYSIS | Non-Final OA | The Regents of the University of California |
| 18512522 | MODULATING BONE MORPHOGENIC PROTEIN (BMP) SIGNALING IN THE TREATMENT OF ALZHEIMER'S DISEASE | Final Rejection | The Board of Trustees of the Leland Stanford Junior University |
| 18229117 | Methods of Treating Metastatic Castration-Resistant Prostate Cancer with Bispecific Anti-PSMA x Anti-CD28 Antibodies in Combination with Anti-PD-1 Antibodies | Final Rejection | Regeneron Pharmaceuticals, Inc. |
| 16863800 | METHODS FOR TREATING OR PREVENTING ASTHMA BY ADMINISTERING AN IL-33 ANTAGONIST | Final Rejection | REGENERON PHARMACEUTICALS, INC. |
| 18285125 | MAGEB2 BINDING CONSTRUCTS | Non-Final OA | Amgen Inc. |
| 18286903 | Digital Protein Misfolding Assays | Non-Final OA | President and Fellows of Harvard College |
| 17310262 | METAL CHELATOR COMBINATION THERAPY FOR THE TREATMENT OF CANCER | Non-Final OA | Board of Regents, The University of Texas System |
| 18146014 | COMBINATION OF AN ANTI-PD-L1 ANTIBODY AND A DNA-PK INHIBITOR FOR THE TREATMENT OF CANCER | Non-Final OA | Pfizer Inc. |
| 17997298 | COMPOSITIONS AND METHODS OF ADAMTS13 CHIMERIC AUTOANTIBODY RECEPTOR CELLS | Final Rejection | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 16755590 | ANTI-CD45-BASED LYMPHODEPLETION METHODS AND USES THEREOF IN CONJUNCTION WITH ACT-BASED CANCER THERAPIES | Non-Final OA | Actinium Pharmaceuticals, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy59.6% of resolved applications examined by Peter N. Johansen were allowed (228 resolved cases), compared with 45.2% across Art Unit 1641 over the last five years.
This examiner's interview lift is +24.4 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Peter N. Johansen took 1,221 days on average from filing to allowance.
Peter N. Johansen examines applications in Art Unit 1641 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
